Harrow, Inc.

XNASHealth care

Last traded price · USD

$28.99

+0.83%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 16:00 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $28.75
Volume: 109
Day's high: —
Day's low: —

In brief

Harrow, Inc. is a health care company listed on Nasdaq, valued at about $1.09B.
Its shares closed at $28.75 on 4 Nov 2026, down 18.6% over the past year.
From India you can buy HROW in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Harrow, Inc. (HROW) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole HROW share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade HROW options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −5.3% (SPY −1.6%, XLV +13.5%). 3 months: −27.0% (SPY −0.4%, XLV +15.5%). 1 year: −18.6% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: HROW, SPY and XLV · as of 4 Nov 2026
11.2 days to cover short interest
7.5M shares were sold short at the 15 Oct 2026 settlement, 19.9% of the 37.5M shares outstanding; covering them would take 11.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
6.6% above its 52-week low
Closed at $28.75 on 4 Nov 2026: 47.6% below the 52-week high of $54.85 (7 Jan 2026) and 6.6% above the low of $26.96 (14 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $28.75 was 10.5% below its 50-day average ($32.13) and 24.5% below its 200-day average ($38.06). It has closed below the 200-day for 50 sessions, since 26 Aug 2026. The 50-day average crossed below the 200-day on 28 Aug 2026, 47 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−5.3%

6 months−28.6%

1 year−18.6%

5 years+139.6%

Newswire

About

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

Website

Notable moves

August 8, 2024
+54.32%
May 14, 2024
+34.55%
November 14, 2023
−36.01%

Newswire

About

Website

Notable moves

August 8, 2024
+54.32%
May 14, 2024
+34.55%
November 14, 2023
−36.01%

Harrow, Inc.

XNASHealth care

Last traded price · USD

$28.99

+0.83%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 16:00 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $28.75
Volume: 109
Day's high: —
Day's low: —

In brief

Harrow, Inc. is a health care company listed on Nasdaq, valued at about $1.09B.
Its shares closed at $28.75 on 4 Nov 2026, down 18.6% over the past year.
From India you can buy HROW in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Harrow, Inc. (HROW) shares from India?

Do I need the price of a whole HROW share to invest?

How much can I invest in US stocks in a year?

Can I trade HROW options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −5.3% (SPY −1.6%, XLV +13.5%). 3 months: −27.0% (SPY −0.4%, XLV +15.5%). 1 year: −18.6% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: HROW, SPY and XLV · as of 4 Nov 2026
11.2 days to cover short interest
7.5M shares were sold short at the 15 Oct 2026 settlement, 19.9% of the 37.5M shares outstanding; covering them would take 11.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
6.6% above its 52-week low
Closed at $28.75 on 4 Nov 2026: 47.6% below the 52-week high of $54.85 (7 Jan 2026) and 6.6% above the low of $26.96 (14 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $28.75 was 10.5% below its 50-day average ($32.13) and 24.5% below its 200-day average ($38.06). It has closed below the 200-day for 50 sessions, since 26 Aug 2026. The 50-day average crossed below the 200-day on 28 Aug 2026, 47 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−5.3%

6 months−28.6%

1 year−18.6%

5 years+139.6%

Newswire

About

Website

Notable moves

August 8, 2024
+54.32%
May 14, 2024
+34.55%
November 14, 2023
−36.01%

Newswire

About

Website

Notable moves

August 8, 2024
+54.32%
May 14, 2024
+34.55%
November 14, 2023
−36.01%

Harrow, Inc.

Harrow, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

11.2 days to cover short interest

6.6% above its 52-week low

Below its 50- and 200-day averages

Harrow, Inc.

Harrow, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

11.2 days to cover short interest

6.6% above its 52-week low

Below its 50- and 200-day averages